Sorafenib

From Proteopedia

Jump to: navigation, search

Sorafenib, also known as Nexavar, (3heg)

References

  1. http://quicktake.morningstar.com/Stocknet/san.aspx?id=358559
  2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):125-34. PMID:17215530 doi:10.1056/NEJMoa060655
  3. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. gastrointestinal stromal tumors. Cancer Genet Cytogenet. 2002 May;135(1):1-22. PMID:12072198
  4. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 Oct;7(10):3129-40. PMID:18852116 doi:10.1158/1535-7163.MCT-08-0013

Proteopedia Page Contributors and Editors (what is this?)

David Canner, Joel L. Sussman

Personal tools